Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioXcel Therapeutics, Inc. (BTAI : NSDQ)

• Company Description    BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States. Number of Employees: 29

• Price / Volume Information    Yesterday's Closing Price: $1.13 Daily Weekly Monthly 20 Day Moving Average: 629,650 shares Shares Outstanding: 30.88 (millions) Market Capitalization: $34.89 (millions) Beta: 0.31 52 Week High: $8.08 52 Week Low: $1.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.73% -2.29% 12 Week -35.80% -40.65% Year To Date -29.37% -34.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 555 Long Wharf Drive - New Haven,CT 06511 USA ph: 475-238-6837 fax: - nic.johnson@russopartnersllc.com http://www.bioxceltherapeutics.com

• General Corporate Information    Officers Vimal Mehta - Chief Executive Officer and President Peter Mueller - Chairman Richard Steinhart - Chief Financial Officer Javier Rodriguez - Senior Vice President; Chief Legal Officer and Cor June Bray - Director Peer Information BioXcel Therapeutics, Inc. (CORR.) BioXcel Therapeutics, Inc. (RSPI) BioXcel Therapeutics, Inc. (CGXP) BioXcel Therapeutics, Inc. (BGEN) BioXcel Therapeutics, Inc. (GTBP) BioXcel Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09075P204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 30.88 Most Recent Split Date: 2.00 (0.06:1) Beta: 0.31 Market Capitalization: $34.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.07 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 30.30% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 51.31 EPS Growth vs. Year Ago Period: 64.00% vs. Previous Quarter: 6.90% Sales Growth vs. Year Ago Period: 22.62% vs. Previous Quarter: -19.53% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -201.53 12/31/25 - -181.48 09/30/25 - -185.00 Current Ratio 03/31/26 - 0.62 12/31/25 - 0.83 09/30/25 - 1.17 Quick Ratio 03/31/26 - - 12/31/25 - 0.82 09/30/25 - 1.16 Operating Margin 03/31/26 - -11,078.53 12/31/25 - -10,887.38 09/30/25 - -9,070.61 Net Margin 03/31/26 - -11,078.53 12/31/25 - -10,887.38 09/30/25 - -9,070.61 Pre-Tax Margin 03/31/26 - -11,078.53 12/31/25 - -10,887.38 09/30/25 - -9,070.61 Book Value 03/31/26 - -3.42 12/31/25 - -4.37 09/30/25 - -4.45 Inventory Turnover 03/31/26 - 0.79 12/31/25 - 0.28 09/30/25 - 1.68 Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©